LGD 6972

Drug Profile

LGD 6972

Alternative Names: Compound G; Compound H; Cpd G; Cpd H; GCGR Antagonist Program - Ligand Pharmaceuticals; GRA; LGD-6972; LGD-6972 sodium salt; MB-11262

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 11 Sep 2017 Pharmacokinetics, adverse events and pharmacodynamics data from a phase I trial in Type 2 diabetes presented at 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD - 2017)
  • 05 Sep 2017 Pharmacodynamic data from preclinical studies in Type 2 diabetes released by Ligand Pharmaceuticals
  • 05 Sep 2017 Top-line efficacy and adverse events data from phase II trial in Type 2 diabetes released by Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top